GLPwatch
Exenatide vs Survodutide
Molecule comparison
Last updated 2026-05-28 15:46 UTCExenatide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, available as Byetta or Bydureon. Survodutide is a dual-acting drug that targets both GLP-1 and glucagon receptors and is still in development, with no FDA approvals yet.
AI summary of the sources below.
| Exenatide | Survodutide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Glucagon and GLP-1 receptor dual agonist |
| Status | Approved | Pipeline |
| Branded products | byetta, bydureon | — |
Compare full details on the Exenatide and Survodutide pages.